Quantitative Medicine is a computational biology company that developed data analytics software-as-a-service (SaaS) for drug development purposes. It was established in 2012 by Joshua D. Kangas, Robert Murphy, Scott R. Bodine. Quantitative Medicine was acquired by Predictive Oncology in January 2020. The company is headquartered in Pittsburgh, Pennsylvania, United States.
Quantitative Medicine's SaaS is called the Computational Research Engine (CoRE). It is used to accelerate drug development through the use of predictive analytics. The function is aimed at reducing testing intensity during the drug discovery and pre-clinical study phases. CoRE utilizes a database of existing therapeutical experiments in various drug development stages to generate testing results on the new drug compound based on the most similar conditions. However, Quantitative Medicine prefers that the software is used as a supporting mechanism to the crucial drug testing phases, instead of acting as their replacement.
Computational Research Engine (CoRE) Overview